Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS View Full Press Release Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress